The board of GN Store Nord with Chairman Per Wold-Olsen at the Helm opposed LD Pensions' and Akademikerpension's shareholder proposals that tax information should be made public on a country-by-country basis as per 2021. The proposal was supported by boards in many other C25 companies, such as Chr. Hansen, Coloplast, Carlsberg ans FLSmidth.
GN's board, however, could not pull a majority against the proposal of looking into the possibility of increasing the transparency of GN's tax payments. The board's motion to dismiss the proposal had no effect on the shareholders. The proposal was passed at the general assembly with two-thirds of the votes, and with the support of for example Danske Bank, Nordea and Vanguard.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Diabetes center CEO: New Eli Lilly drug is worthy opponent for Novo Nordisk's Ozempic
Allan Flyvbjerg, CEO of Steno Diabetes Center in Copenhagen, says Eli Lilly’s tirzepatide has proved itself a fierce challenger to Novo Nordisk’s newest generation of diabetes drugs.
In a world of options, Genmab's CEO chose partnerships
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.
Analyst predicts slow start for Leo Pharma's Adtralza in UK
The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.
US government exercises option to buy Bavarian smallpox vaccines for USD 119m
The first option in an existing contract with the US has been utilized, and Bavarian Nordic can start manufacturing freeze-dried doses of Jynneos for the country in 2023.
Issues at Novo Nordisk lead to shortage of fast-acting diabetes drug
The Danish Medicines Agency has reported that it is currently difficult to find diabetes drug Novorapid in Denmark.
IRT Manager, Clinical Drug Supply 
Chemist for Incoming Materials in QC Department 
Clinical Trial Manager 
2 Sales Representatives and Product Specialists 
Account Manager 
Communications Consultant 
Procurement Process Excellence Specialist 
Director Global Engineering 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Senior QA Specialist 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Key Account Manager, Europe and Asia 
Client Talent Acquisition Specialist 
Vice President, Test & Characterisation 
Analytical Coordinator for Analytical Development 
Nordic Medical Affairs Manager